| Covenant Family Solutions, Llc | |
|
1655 Blairs Ferry Rd Marion IA 52302 | |
| (319) 261-2292 | |
| (319) 333-0992 |
| Full Name | Covenant Family Solutions, Llc |
|---|---|
| Speciality | Community/Behavioral Health |
| Location | 1655 Blairs Ferry Rd, Marion, Iowa |
| Authorized Official Name and Position | Jacob Dustin Christenson (CEO) |
| Authorized Official Contact | 3192612292 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Covenant Family Solutions, Llc 1655 Blairs Ferry Rd Marion IA 52302-3157 Ph: (319) 261-2292 | Covenant Family Solutions, Llc 1655 Blairs Ferry Rd Marion IA 52302 Ph: (319) 261-2292 |
| NPI Number | 1407295280 |
|---|---|
| Provider Enumeration Date | 06/14/2013 |
| Last Update Date | 12/11/2018 |
| Medicare PECOS PAC ID | 2264738756 |
|---|---|
| Medicare Enrollment ID | O20160309001544 |
News Archive
The U.N. on Wednesday "presented a plan to make life-saving health supplies more accessible, while a new report found that, despite impressive reductions in maternal and child mortality in the past decade in some countries, millions of women and children still die every year from preventable causes," the U.N. News Centre reports.
The Institute for OneWorld Health (iOWH) announced a major milestone in the fight against cholera. The Food and Drug Administration (FDA) granted iOWH permission to begin phase 1 trials for iOWH032, a drug to treat secretory diarrhea. This is the first submission of an Investigational New Drug application for a completely new chemical entity by a non-profit of this size to receive such rapid FDA clearance, and it could be the first synthetic drug of its kind for diarrheal diseases.
Those who have leukemia, lymphoma or other blood cancer diseases might have heard about bone marrow transplant as a potential treatment. As with any serious procedure, it is important to have all questions answered by a physician before any decision is made.
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407295280 | NPI | - | NPPES |
| 600879703 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | (* (Not Available)) | Primary |
| Provider Name | Timothy A Griem |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1689637696 PECOS PAC ID: 6002087939 Enrollment ID: I20110926000145 |
News Archive
The U.N. on Wednesday "presented a plan to make life-saving health supplies more accessible, while a new report found that, despite impressive reductions in maternal and child mortality in the past decade in some countries, millions of women and children still die every year from preventable causes," the U.N. News Centre reports.
The Institute for OneWorld Health (iOWH) announced a major milestone in the fight against cholera. The Food and Drug Administration (FDA) granted iOWH permission to begin phase 1 trials for iOWH032, a drug to treat secretory diarrhea. This is the first submission of an Investigational New Drug application for a completely new chemical entity by a non-profit of this size to receive such rapid FDA clearance, and it could be the first synthetic drug of its kind for diarrheal diseases.
Those who have leukemia, lymphoma or other blood cancer diseases might have heard about bone marrow transplant as a potential treatment. As with any serious procedure, it is important to have all questions answered by a physician before any decision is made.
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
› Verified 7 days ago
News Archive
The U.N. on Wednesday "presented a plan to make life-saving health supplies more accessible, while a new report found that, despite impressive reductions in maternal and child mortality in the past decade in some countries, millions of women and children still die every year from preventable causes," the U.N. News Centre reports.
The Institute for OneWorld Health (iOWH) announced a major milestone in the fight against cholera. The Food and Drug Administration (FDA) granted iOWH permission to begin phase 1 trials for iOWH032, a drug to treat secretory diarrhea. This is the first submission of an Investigational New Drug application for a completely new chemical entity by a non-profit of this size to receive such rapid FDA clearance, and it could be the first synthetic drug of its kind for diarrheal diseases.
Those who have leukemia, lymphoma or other blood cancer diseases might have heard about bone marrow transplant as a potential treatment. As with any serious procedure, it is important to have all questions answered by a physician before any decision is made.
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
› Verified 7 days ago
Labase Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2810 25th Ave, Marion, IA 52302 Phone: 319-777-8705 | |
Connecting Youth Achievement Center & Consulting Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2494 Roycroft Aly, Marion, IA 52302 Phone: 319-408-8138 | |
Victory Family Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1175 8th Ave, Marion, IA 52302 Phone: 319-261-1717 Fax: 319-377-8147 | |
Praxis Girl, Pc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 642 10th St Ste 101, Marion, IA 52302 Phone: 319-440-7923 | |
Principles Counseling Group, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2635 Lynn Dr, Marion, IA 52302 Phone: 641-691-3917 | |
Abbe Center For Cmh At Abbe Center For Community Care Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1860 County Home Rd, Marion, IA 52302 Phone: 319-398-3562 Fax: 319-398-3501 |